Open AccessTreatment with Clodronate in Patients with Hypercalcemia Secondary to Malignancy
Author(s) -
Lars Lind,
Bo Wengle,
Sverker Ljunghall
Publication year - 1987
Publication title -
upsala journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.808
H-Index - 41
eISSN - 2000-1967
pISSN - 0300-9734
DOI - 10.3109/03009738709178696
Subject(s) - medicine , concomitant , malignancy , bisphosphonate , bone resorption , drug , urology , gastroenterology , osteoporosis , pharmacology
Dichloromethylene bisphosphonate (clodronate, Cl2MDP) is a synthetic analogue to pyrophosphate, which inhibits increased bone resorption. This drug was given to 12 patients with hypercalcemia secondary to advanced malignant disease. Clodronate in a daily dose of 1.6 to 3.2 g generally caused a return of the serum calcium values to normal within 5-10 days with a concomitant improvement of symptoms related to the hypercalcemia. Side effects were few. Thus, clodronate appears to be a valuable adjunct for the medical management of patients with malignancy-associated hypercalcemia.